Shares of LB Pharmaceuticals Inc (NASDAQ:LBRX – Get Free Report) have been given an average rating of “Moderate Buy” by the eight research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $38.40.
LBRX has been the topic of a number of research reports. Roth Mkm reissued a “buy” rating and set a $37.00 target price on shares of LB Pharmaceuticals in a report on Sunday, May 17th. Wall Street Zen raised shares of LB Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday. Craig Hallum initiated coverage on shares of LB Pharmaceuticals in a report on Friday, April 10th. They set a “buy” rating and a $36.00 target price on the stock. Weiss Ratings raised shares of LB Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Finally, Stifel Nicolaus boosted their target price on shares of LB Pharmaceuticals from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, March 27th.
View Our Latest Stock Report on LB Pharmaceuticals
LB Pharmaceuticals Trading Up 0.1%
LB Pharmaceuticals (NASDAQ:LBRX – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.08. As a group, research analysts anticipate that LB Pharmaceuticals will post -3.58 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. California State Teachers Retirement System acquired a new position in shares of LB Pharmaceuticals in the 4th quarter worth approximately $26,000. Bank of America Corp DE acquired a new position in shares of LB Pharmaceuticals in the 3rd quarter worth approximately $27,000. Russell Investments Group Ltd. acquired a new position in shares of LB Pharmaceuticals in the 4th quarter worth approximately $34,000. Strs Ohio acquired a new position in shares of LB Pharmaceuticals in the 4th quarter worth approximately $76,000. Finally, Persistent Asset Partners Ltd acquired a new position in shares of LB Pharmaceuticals in the 4th quarter worth approximately $91,000.
About LB Pharmaceuticals
We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.
Featured Articles
- Five stocks we like better than LB Pharmaceuticals
- 3 Retail Winners Using Cash Flow to Stay Ahead
- 3 Tech ETFs That Could Bounce Back After the AI Selloff
- 3 Penny Stocks Under $5 Backed by Real Revenue Growth
- 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
Receive News & Ratings for LB Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LB Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
